Hi ,
I am giving a special shout-out to my friends in the North Carolina synthetic biology community for some recent standout success! Raleigh-based Jellatech recently landed $3.5M in seed funding to enable the scale-up of their cutting-edge protein manufacturing platform. Additionally, the plant-based dog food company Wild Earth, out of Durham, NC, just partnered with Petco to launch its fully vegan line of dog food and treats. So, a big congratulations to the North Carolina crew!
Have you tried My®Bacon yet? If you haven't, what are you waiting for!? Ecovative and My®ForestFoods are on a mission to bring biology to scale, which means bringing their delicious plant-based bacon to a thousand stores in the coming year. Their farm-grown mycelium gives MyBacon a remarkable taste and texture. Check out this short video for more information.
|
 |
(Photo: Business Wire)
Pioneering Gene Therapy Results Promising for Rare Liver Disease. In a monumental clinical trial, Généthon's gene therapy emerges as a game-changer, turning the tide against Crigler-Najjar syndrome.
Green is the New Gold: Cascade Biocatalysts Secures $2.6M to Scale Enzyme Technology. Cascade’s breakthrough "Body Armor for Enzymes™" technology gains momentum from pre-seed funding.
Retinol Revolution: Conagen's Sustainable Spin on Skincare. Through precision fermentation, Conagen pioneers a sustainable retinol blend, revolutionizing beauty and personal care formulations
Inside the Belly's Bazaar: Probiotics that Light Up Inflammation. Rice University's bioengineers are turning the spotlight on gut health with their glow-on-demand probiotics, designed to detect inflammation.
Aviation and Maritime Biofuels Get Sustainability Boost from Novel Enzyme. Brazilian researchers unveil OleTPRN, a groundbreaking enzyme poised to redefine the biofuel landscape for global aviation.
Nanovesicles: The Tiny Sacks Engineered to Target Cancer Cells. Gone might be the days of toxic chemotherapies, as Binghamton University pioneers a safer, targeted method using nanovesicles.
A DNA-Based Anticoagulant is Set to Disrupt the Norm. Bridging biochemistry and thrombosis biology, researchers are crafting a revolutionary anticoagulant poised to change the future of blood clot treatments.
Unlocking Nature's Secrets: The Promise of Synthetic Catalysts in Biomass Conversion. Inspired by nature's enzymes, Iowa State scientists’ groundbreaking research into synthetic catalysts offers a sustainable path to biomass conversion.
|
|
|
|
|
|
|
|
|
|
Other news:
|
iGEM Hosts the World Expo of Synthetic Biology in Paris: Experience the largest gathering of synthetic biology from Nov 2 to Nov 5,
2023. Join over 5000 researchers, industry reps, startup founders, investors, journalists, experts in governance and policy, and the general public to chart the future of synthetic biology.
Genesis Therapeutics Closes Oversubscribed $200 Million Series B. The funds will be used to advance Genesis’ existing wholly-owned pipeline of AI-enabled programs into clinical development. (Press release)
Aether Raises $49M in Series A Funding. Aether, a Menlo Park, CA-based nanoscale machinery company that can assemble new classes of molecules to create enhanced products, raised $49M in Series A funding. (FinSMEs)
Scottish startup ENOUGH raises €40m for its alternative meat. Founded in 2015, ENOUGH has now raised more than €95m, making it Europe’s best-funded mycoprotein startup (Sifted)
Innovate Illinois, led by Governor JB Pritzker, has supported two groundbreaking projects in a collaborative effort to secure federal funding made available by the Bipartisan Infrastructure Bill, the CHIPS and Science Act, and the Inflation Reduction Act.
Global Life Sciences/Healthcare Startup Class Briefing. Learn about UCSF's renowned global entrepreneurship course that starts on October 4th.
Regards,
John
---
John Cumbers
CEO, SynBioBeta
|
Who's hiring?
|
|
|
|
|
|
|
|
